Innovent Constructing Biologic Facility in Suzhou
Innovent Biologics, a Suzhou company formed last year, is building a biotech plant in BioBay. The company has two aims: it intends to in-license biotech drugs for the China market, and it also wants to provide contract manufacturing services to other companies. The company is led by an international management team of experienced biotech executives. With $30 million in startup capital from Fidelity, Lilly Ventures and Suzhou BioBay, Innovent has instant credibility. More details.... Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});  
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here